A correlation between IL-8 serum levels and reduced clinical benefit of ICIs in patients with melanoma, NSCLC, hepatocellular carcinoma and renal cancer was first reported by Sanmamed et al. The gene discussed is CXCL8; the disease is renal carcinoma.